SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Cheryl Galt who wrote (26023)10/7/1998 4:10:00 AM
From: Skeeter Bug  Read Replies (1) | Respond to of 32384
 
does panretin impact psoriasis? if so, the market could be huge. cosmocuedicals (sp??) can be HUGE.



To: Cheryl Galt who wrote (26023)10/7/1998 7:41:00 AM
From: Henry Niman  Respond to of 32384
 
Cheryl, I think that the current Panretin psoriasis Phase II trial is completed and I believe that it is for Panretin oral. I don't that that any Panretin topical trial has begun (other than the completed KS trial).



To: Cheryl Galt who wrote (26023)10/7/1998 8:29:00 AM
From: Hippieslayer  Read Replies (2) | Respond to of 32384
 
Re: Psoriasis

Everyone including my grandmother is trying to come up with the silver bullet for this disease. One has to wonder if Pan. is effective in treating this, why didn't they push it for this "large" disease instead of KS? But let's assume that if Pan is approved, it could most well be prescribed off label for Psoriasis. This is what those slicksters at LGND are probably hoping for. Sounds like a plan, stan.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News